Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$1.93 USD
+0.05 (2.66%)
Updated May 1, 2024 04:00 PM ET
After-Market: $2.70 +0.77 (39.90%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EBS 1.93 +0.05(2.66%)
Will EBS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EBS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EBS
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
EBS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
Emergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
Other News for EBS
Emergent Biosolutions: Q1 Earnings Snapshot
Emergent BioSolutions Reports First Quarter 2024 Financial Results
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
EBS Stock Earnings: Emergent BioSolutions Beats EPS, Beats Revenue for Q1 2024